VIPER from Deep Lens aims to rapidly and effectively match patients with precision therapies and clinical studies.
More than 15,000 oncology clinical trials are actively recruiting patients, yet estimates put the rate of participation as low as three percent of potential trial candidates. And with the onset of the COVID-19 pandemic, many medical institutions have suspended or ended clinical trials. “As a result of the pandemic, healthcare institutions have a COVID-19 protocol to minimize patients to only those necessary,” said Simon Arkell, president and co-founder of Deep Lens, in an interview with MD+DI. Many cancer patients, survivors, and those in remission have also heeded warnings about staying inside and distancing from others, he said, because these patients’ immune systems remain compromised.